Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 10:00 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2257–2280 of 6,233 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Part 1 Clear all

Conditions: Advanced Solid Tumors, Gastric Cancer, Transitional Cell Carcinoma of the Bladder
Interventions: FPA144; Drug
Lead sponsor: Five Prime Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 13
States / cities: Duarte, California • Los Angeles, California • San Francisco, California + 9 more

Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Triple-Negative Breast Carcinoma, Metastatic Urothelial Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions: Atezolizumab, Cyclophosphamide, Fludarabine, MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells, PD1 Inhibitor; Drug · Biological
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Muscular Atrophy, Spinal
Interventions: risdiplam, omeprazole; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 131 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 4
States / cities: Daytona Beach, Florida • Springfield, Missouri • Dallas, Texas + 1 more

Conditions: Burnout, Professional
Interventions: hybrid asynchronous-synchronous group coaching program, treatment as usual group (TAU); Behavioral · Other
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 319 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 4
States / cities: Denver, Colorado • Atlanta, Georgia

Conditions: Hepatic Impairment
Interventions: Danicopan; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 2
States / cities: Miami, Florida • Orlando, Florida

Conditions: Atopic Dermatitis
Interventions: BBT001, Placebo; Drug
Lead sponsor: Bambusa Therapeutics; Industry
Eligibility: 18 Years to 72 Years
Enrollment: 237 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 3
States / cities: Irvine, California • New York, New York • The Bronx, New York

Conditions: Coronary Artery Disease
Interventions: [O-15]-Water PET Myocardial Perfusion Imaging (MPI); Drug
Lead sponsor: MedTrace Pharma A/S; Industry
Eligibility: 18 Years and older
Enrollment: 232 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 6
States / cities: Iowa City, Iowa • Rochester, Minnesota • St Louis, Missouri + 3 more

Conditions: Rheumatoid Arthritis
Interventions: Abatacept, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 738 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2009
U.S. locations: 42
States / cities: Birmingham, Alabama • Mobile, Alabama • Paradise Valley, Arizona + 39 more

Conditions: Peripheral Artery Disease
Interventions: Exercise, Attention control; Behavioral · Other
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 305 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 4
States / cities: Chicago, Illinois • New Orleans, Louisiana • Minneapolis, Minnesota + 1 more

Conditions: Multiple Chronic Conditions, Dementia
Interventions: Patient Priorities Care (PPC) Approach, Adapted PPC; Behavioral
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 60 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: PTSD
Interventions: MDMA, Cognitive Processing Therapy, MDMA-assisted Cognitive Processing Therapy (MDMA-aCPT); Drug · Behavioral
Lead sponsor: Patricia Suppes; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Fibromyalgia, Healthy Volunteers
Interventions: EEG, Neuroimaging EEG/fMRI (Aim 1), HD-tDCS treatments, Sham HD-tDCS treatments, Neuroimaging EEG/fMRI (Aim 3); Diagnostic Test · Device
Lead sponsor: University of Michigan; Other
Eligibility: 19 Years to 74 Years
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Patients With Principal or Secondary Diagnosis Code of Intrntl Classification of Diseases, 9th Revision, (ICD-9-CM) 410 (Except When 5th Digit Was 2)
Interventions: Electronic Pill Bottle, Incentives, Social Influence; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 80 Years
Enrollment: 1,509 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
Interventions: ZW25 (Zanidatamab), Capecitabine, Cisplatin, Fluorouracil, Leucovorin, Oxaliplatin, Bevacizumab, Gemcitabine; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 11
States / cities: Los Angeles, California • Newport Beach, California • Tampa, Florida + 8 more

Conditions: Alzheimer Disease
Interventions: Gantenerumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: Not listed
Enrollment: 1,382 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 67
States / cities: Phoenix, Arizona • Sun City, Arizona • Fayetteville, Arkansas + 58 more

Conditions: Aortic Aneurysm, Thoracoabdominal, Aortic Aneurysm, Thoracic, Aortic Dissection, Thoracoabdominal
Interventions: Endovascular treatment of Thoracoabdominal Aortic Aneurysm, Endovascular treatment of Aortic Arch Aneurysms; Device
Lead sponsor: Darren Schneider, M.D.; Other
Eligibility: 18 Years and older
Enrollment: 520 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2033
U.S. locations: 2
States / cities: New York, New York • Philadelphia, Pennsylvania

Conditions: Obesity
Interventions: LY3532226, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 3
States / cities: Daytona Beach, Florida • Dallas, Texas • Madison, Wisconsin

Conditions: FAP, Familial Adenomatous Polyposis
Interventions: R-1,3-Butanediol (10G-A), R-1,3-Butanediol (20G-A), R-1,3-Butanediol (30G-A), R-1,3-Butanediol (30G-B); Dietary Supplement
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Non-small Cell Lung Cancer
Interventions: gemcitabine, docetaxel, cisplatin, etoposide, radiation therapy; Drug · Radiation
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 10
States / cities: Denver, Colorado • South Bend, Indiana • Baltimore, Maryland + 7 more

Conditions: Glioma
Interventions: rhIL-7-hyFc, Placebo, Temozolomide, Radiation therapy; Drug · Radiation
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Skin Laxity
Interventions: 2910 nm Fiber Laser Treatment; Pre-Clinical Histology Evaluation, 2910 nm Fiber Laser Treatment; Part 2 Histology Evaluation; Device
Lead sponsor: FA Corporation; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
Interventions: Cryosurgery, Pembrolizumab, Pheresis, Therapeutic Autologous Dendritic Cells; Procedure · Biological
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Bioequivalence, Fixed Dose Combination Tablets, Healthy Male and Female Subjects
Interventions: dapagliflozin/metformin XR 5/500 mg test drug (Mount Vernon), dapagliflozin/metformin XR 5/500 mg reference drug (Humacao), dapagliflozin/metformin XR 10/1000 mg test drug (Mount Vernon), dapagliflozin/metformin XR 10/1000 mg reference drug (Humacao); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Colorectal Cancer
Interventions: bevacizumab, FOLFOX regimen, fluorouracil, leucovorin calcium, oxaliplatin, ursodiol, RNA analysis, gene expression analysis, polymerase chain reaction, western blotting, immunohistochemistry staining method, laboratory biomarker analysis, pharmacological study, positron emission tomography (PET); Biological · Drug · Genetic + 2 more
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2025
U.S. locations: 1
States / cities: Duarte, California

Search by objective public record fields.

Open-Label, Dose-Finding Study Evaluating Safety and PK of FPA144 in Patients With Advanced Solid Tumors

Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer

Bioavailability and Bioequivalence of Two Risdiplam Tablets in Healthy Participants

Coaching for Advanced Practice Providers

Study of Danicopan in Participants With Hepatic Impairment

A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Atopic Dermatitis (AD)

RAdiolabeled Perfusion to Identify Coronary Artery Disease Using WAter To Evaluate Responses of Myocardial FLOW (RAPID-WATER-FLOW)

Phase III Study of BMS-188667 (CTLA4Ig) in Patients With Rheumatoid Arthritis Who Are Currently Failing Anti-TNF Therapy or Who Have Failed Anti-TNF Therapy in the Past.

Low InTensity Exercise Intervention in PAD

Patient Priorities Care for Hispanics With Dementia

MDMA-assisted Cognitive Processing Therapy Versus Cognitive Processing Therapy for Veterans With Severe Posttraumatic Stress Disorder

Explosive Synchronization of Brain Network Activity in Chronic Pain

Automated Hovering to Improve Medication Adherence Among Myocardial Infarction Patients (Heartstrong)

A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer

A Study to Evaluate the Safety, Tolerability, and Efficacy of Long-Term Gantenerumab Administration in Participants With Alzheimer's Disease (AD)

Endovascular Treatment of TAAA and Aortic Arch Aneurysms Using Fenestrated and Branched Stent Grafts

A Study of LY3532226 in Participants With Obesity

Investigation of β-hydroxybutyrate Supplementation as Chemoprevention in Familial Adenomatous Polyposis

Gemcitabine or Gemcitabine Plus Docetaxel After Cisplatin, Etoposide and Radiation in Non Small Cell Lung Cancer (NSCLC)

rhIL-7-hyFc on Increasing Lymphocyte Counts in Patients With Newly Diagnosed Non-severe Lymphopenic Gliomas Following Radiation and Temozolomide

Histological Study of the Effects of a 2910 nm Fiber Laser Technology

Dendritic Cell Therapy With Pembrolizumab for Metastatic or Unresectable Melanoma

A Study to Assess the Bioequivalence of Dapagliflozin/Metformin XR Fixed-dose Combination Tablets in Healthy Subjects

Ursodiol, Combination Chemotherapy, and Bevacizumab in Treating Patients With Stage IV Colorectal Cancer